News >

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

Silas Inman @silasinman
Published: Saturday, Dec 09, 2017

Dr Hope Rugo

Hope S. Rugo, MD
The combination of abemaciclib (Verzenio) and pembrolizumab (Keytruda) showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer, according to early results from a pilot trial presented in a poster at the 2017 San Antonio Breast Cancer Symposium (SABCS).1

In the JPCE trial, the partial response (PR) rate at 16 weeks was 14.3% and it was 6.8% in the MONARCH-1 trial. There were no complete responses in either trial. The rate of stable disease was similar between both trials at 60.7% in JPCE and 60.6% in MONARCH-1. Fewer patients had developed progressive disease in the JPCE trial (17.9% and 25.0%). In JPCE, the disease control rate (DCR) was 75% and in MONARCH-1 it was 67.4% at the early assessment.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication